Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

WILEX receives acquisition offer from lifesciences advisor

This article was originally published in Clinica

  • News
  • Joseph Harvey  

Executive Summary

WILEX has received a takeover bid of €4.10 per share from fellow German firm dievini Hopp BioTech. Under German law, lifesciences management advisor dievini is obliged to make an offer after it gained a 35.65% equity interest in WILEX on 2 June. The acceptance period for the offer runs from today until 12 August. WILEX (Munich) is a biopharmaceutical firm that develop drugs as well as diagnostic agents, such as radiolabelled antibodies, for the specific detection of tumours. Walldorf-based dievini consists of a team of experts in medicine, science, finance, legal and entrepreneurship, and is in charge of accompanying investors, management and enterprises.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

UK MHRA Updates Assistive Tech And Borderline Regulations

See All
UsernamePublicRestriction

Register

MT095155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By